A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia

Journal of Medical Screening

Volumn 21, Issue 3, 2014, Pages 151-162

  Morrell, Stephen ^a,b   Qian, Liping ^a  

^a CANCER INSTITUTE NSW   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cervical dysplasia; Cytology; Hpv testing; Human papilloma virus; Test of cure

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; CYTOLOGY; FEMALE; HPV TESTING; HUMAN; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; TEST OF CURE; UTERINE CERVIX DYSPLASIA; VIROLOGY; WART VIRUS;

CERVICAL DYSPLASIA; CYTOLOGY; HPV TESTING; HUMAN PAPILLOMA VIRUS; TEST OF CURE;

ADULT; AGED; FEMALE; HUMANS; MIDDLE AGED; NEW SOUTH WALES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA;

EID: 84908481643     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141314542667     Document Type: Article

References (21)

1. Arbyn M, Sasieni P, Meijer C, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (Suppl 3): S3/78–S3/89.
2. Alonso I, Torné A, Puig-Tintoré L, Esteve R, Quinto L, Campo E, Pahisa J, Ordi J. Pre-and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006; 103:631–636.
3. Verguts J, Bronselaer B, Donders G, Arbyn M, Eldere JV, Drijkoningen M, Poppe W. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 2006; 113:1303–1307.
4. Alonso I, Torné A, Puig-Tintoré L, Esteve R, Quinto L, Garcia S, Campo E, Pahisa J, Ordi J. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. Am J Obstet Gynecol 2007; 197:359.e1–359.e6.
5. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol 2007; 106:170–176.
6. Bae J, Kim C, Park T, Namkoong S, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 2007; 17:1271–1277.
7. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, Zerbini M. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 2008; 80:1434–1440.
8. Takac I. Human papillomavirus infection in patients with residual or recurrent cervical intraepithelial neoplasia. Tumori 2008; 94:83–86.
9. Prato B, Ghelardi A, Gadducci A, Marchetti I, Cristofano CD, Coscio GD, Bevilacqua G, Genazzani A. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer 2008; 18:90–94.
10. Jeong N, Lee N, Kim H, Kim TK, Lee KW. High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia. J Obstet Gynaecol Res 2009; 35:706–711.
11. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Human papillomavirus test after conization in predicting residual disease in subsequent hysterectomy specimens. Obstet Gynecol 2009; 114:87–92.
12. Aerssens A, Claeys P, Beerens E, Garcia A, Weyers S, Renterghem LV, Praet M, Temmerman M, Ve-lasquez R, Cuvelier C. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia. Cytopathology 2009; 20:27–35.
13. Baloglu A, Uysal D, Bezircioglu I, Bicer M, Inci A. Residual and recurrent disease rates following LEEP treatment in high-grade cervical intraepithelial lesions. Arch Gynecol Obstet 2010; 282:69–73.
14. Smart O, Sykes P, Macnab H, Jennings L. Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions. Aust N Z J Obstet Gynaecol 2010; 50:164–167.
15. Kang W, Oh M, Kim S, Nam J, Park C, Choi H. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol 2010; 203:72.e1–72.e6.
16. Wu D, Zheng Y, Chen W, Guo C, Yu J, Chen G, Huang Y. Prediction of residual/recurrent disease by HPV genotype after loop excision procedure for high-grade cervical intraepithelial neoplasia with negative margins. Aust N Z J Obstet Gynaecol 2011; 51:114–118.
17. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, Sargent A, Wood J, Moore C, Cruickshank ME. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008; 115:1001–1007.
18. National Health and Medical Research Council. Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Commonwealth of Australia, 2005.
19. National Cervical Screening Program. Minimum National Standards for Follow-up and Reminder Pro-tocols for Cytology Registers. Australian Government Department of Health, 2011.
20. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J, NTfCCs WG. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7:547–555.
21. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankara-narayanan R, Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88–F99.